A recent hearing at the Federal Circuit has spotlighted a legal confrontation involving a medical training startup and Galderma, a pharmaceutical company. The startup accuses Galderma of employing a “classic catch-and-kill strategy” to sabotage a prospective $100 million deal with Allergan. The details emerged as the startup pushed for the revival of claims linked to this aborted transaction. However, a three-judge panel expressed reservations about whether the allegations had been adequately detailed in previous proceedings. More information can be found in Law360’s report on the matter.
The panel’s scrutiny stems from the complexity and the potential ramifications of the startup’s theory, which suggests that Galderma’s actions effectively quelled competition that might have reshaped the market dynamics. The intricacies of “catch-and-kill” tactics, commonly used to describe strategies aimed at acquiring rival innovations or businesses only to discontinue them, are under the microscope.
Similar cases have historically indicated the challenge of proving such tactics in court. An article by Reuters highlights the burden required to demonstrate intent and causality, essential in substantiating claims of anti-competitive behavior. Moreover, such allegations demand significant evidence showing that the accused party knowingly and intentionally engaged in acts to stifle competition.
As the case unfolds, the Federal Circuit will dissect previous ruling details and the startup’s assertions. This complex legal battle underscores the scrutiny facing large pharmaceutical mergers and acquisitions. Decisions in such cases often hinge on nuanced interpretations of competition law, potentially setting precedents for how similar disputes might be resolved in the future.